Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ENU 200

Drug Profile

ENU 200

Alternative Names: ENU200

Latest Information Update: 08 Apr 2020

At a glance

  • Originator Ennaid Therapeutics
  • Class Antivirals; Small molecules
  • Mechanism of Action Glycoprotein inhibitors; Peptide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical COVID 2019 infections

Most Recent Events

  • 02 Apr 2020 Ennaid Therapeutics has patent pending for ENU 200
  • 02 Apr 2020 Ennaid Therapeutics plans to launch ENU 200 in COVID-2019 infections (PO) by end-2020
  • 02 Apr 2020 Ennaid Therapeutics plans an in-home phase III trial in COVID-2019 infections (using the company's iClickCare® secure clinical reporting software service) (PO) after discussion with US FDA and other regulatory agencies

Development Overview

Introduction

ENU 200 is being developed as a repurposed, orally deliverable antiviral drug by Ennaid Therapeutics, for the treatment of asymptomatic, mild to moderate COVID-2019 infections. The patent-pending drug, which was earlier approved against other indications, displays antiviral activity against two SARS-CoV-2 proteins, S glycoprotein and Mpro. S glycoprotein of covid virus is a class I viral fusion protein situated on the outer envelope of the virion, which facilitates host cell attachment by recognition of host cell receptors, along with a mediation of host cell membrane and viral membrane fusion during infection. Ennaid's in silico platform proposes that ENU 200 matches the receptor binding domain (RDB) by simultaneously blocking the key residues for binding to ACE2, (Gln493 and Asn501). ENU 200 also blocks CoV main protease (Mpro), which is responsible for CoV replication, and also for conversion of the polypeptide into functional proteins. Data has revealed Mpros as being largely conserved structures. This simultaneous dual blockage, the company believes, will pave the way for expanding treatment landscape for COVID-2019 and other coronaviruses, on account of an enhanced antiviral activity. In vitro and in vivo studies have validated that ENU 200 inhibits viral protease in a different viral infection, and has a good safety profile. Preclinical development is underway in the US.

Ennaid Therapeutics intends to utilise the US FDA's emergency/compassionate use regulatory pathway, or 505(b)(2) application process for ENU 200.

Patent Information

In April 2020, Ennaid Therapeutics reported that it has patent pending for ENU 200 [1] .

Drug Properties & Chemical Synopsis

  • Route of administration PO
  • Formulation unspecified
  • Class Antivirals, Small molecules
  • Target Glycoprotein; Peptide hydrolase
  • Mechanism of Action Glycoprotein inhibitors; Peptide hydrolase inhibitors
  • WHO ATC code

    J05A-X (Other antivirals)

  • EPhMRA code

    J5B (Antivirals, excluding anti-HIV products)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - - Preclinical USA PO / unspecified Ennaid Therapeutics 02 Apr 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
Ennaid Therapeutics Originator USA
Ennaid Therapeutics Owner USA

Future Events

Expected Date Event Type Description Updated
31 Dec 2020 Regulatory Status Ennaid Therapeutics plans to launch ENU 200 in COVID-2019 infections (PO) by end-2020 [1] 08 Apr 2020

Development History

Event Date Update Type Comment
02 Apr 2020 Patent Information Ennaid Therapeutics has patent pending for ENU 200 [1] Updated 08 Apr 2020
02 Apr 2020 Phase Change - Preclinical Preclinical trials in COVID-2019 infections in USA (PO) before April 2020 [1] Updated 08 Apr 2020
02 Apr 2020 Regulatory Status Ennaid Therapeutics plans to launch ENU 200 in COVID-2019 infections (PO) by end-2020 [1] Updated 08 Apr 2020
02 Apr 2020 Trial Update Ennaid Therapeutics plans an in-home phase III trial in COVID-2019 infections (using the company's iClickCare® secure clinical reporting software service) (PO) after discussion with US FDA and other regulatory agencies [1] Updated 08 Apr 2020

References

  1. Ennaid Therapeutics Announces Development of ENU200, A New Antiviral Therapeutic for the Treatment of COVID-19.

    Media Release
Back to top